SNDX — Syndax Pharmaceuticals, Inc. stock price, charts and financials

QT62Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
20.37
-0.03-0.15%
OverviewShort InterestFilings
SNDXQT62Syndax Pharmaceuticals, Inc.·NASDAQ
20.37-0.15%
TA
Loading chart...
Signal & projected range
Earnings big miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.52%$15.45MESO+4.64%$16.68ZBIO-1.48%$31.95GHRS-2.44%$29.53TSHA-2.90%$6.37STOK-1.47%$32.23ABCL+34.78%$9.34VRDN-2.25%$23.06
Snapshot
Index-P/E-EPS (ttm)-2.80Insider Own5.62%Shs Outstand88.61MPerf Week7.09%
Market Cap1.81BForward P/E-EPS next Y-0.67Insider Trans-2.54%Shs Float80.23MPerf Month-17.87%
Enterprise Value2.06BPEG-EPS next Q-Inst Own-Short Float25.95%Perf Quarter-0.68%
Income-219.81MP/S7.17EPS this Y32.61%Inst Trans-Short Ratio10.64Perf Half Y1.24%
Sales252.00MP/B120.23EPS next Y64.39%ROA-31.37%Short Interest20.82MPerf YTD-2.90%
Book/sh-P/C-EPS next 5Y-ROE-372.94%52W High25.55 -20.28%Perf Year58.26%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-32.10%52W Low12.08 68.60%Perf 3Y-0.39%
Dividend Est.-EV/EBITDA-Sales past 3/5Y- 143.72%Gross Margin97.47%Volatility6.62% 5.31%Perf 5Y39.92%
Dividend TTM-EV/Sales8.18EPS Y/Y TTM24.93%Oper. Margin-77.05%ATR (14)1.13Perf 10Y67.63%
Dividend Ex-Date-Quick Ratio6.44Sales Y/Y TTM804.17%Profit Margin-87.60%RSI (14)48.09Recom2.09
Dividend Gr. 3/5Y-Current Ratio6.77EPS Q/Q51.02%SMA20-3.17%Beta0.37Target Price38.00
Payout0.00%Debt/Eq39.03Sales Q/Q225.00%SMA500.02%Rel Volume0.64Prev Close20.40
Employees298LT Debt/Eq5.32EarningsNov 02SMA200-0.36%Avg Volume1.86MPrice20.37
IPO DateMar 02, 2016Option/ShortYes / YesEPS/Sales Surpr.21.02% -7.02%Net Debt/EBITDA-1.87Volume1,188,308Change-0.15%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-05-26ReiteratedHC Wainwright & Co.Buy$40 → $38
Jun-12-26ReiteratedGuggenheimBuy$34 → $31
Jun-03-26ReiteratedH.C. WainwrightBuy$33 → $40
May-04-26ReiteratedStifel Nicolaus$45 → $46
May-01-26ReiteratedBarclaysOverweight$35 → $37
Feb-27-26ReiteratedStifel Nicolaus$44 → $45
Nov-24-25ReiteratedBarclaysOverweight$22 → $35
Nov-04-25ReiteratedUBSBuy$35 → $38
Nov-04-25ReiteratedBarclaysOverweight$33 → $22
Sep-10-25ResumedStifelBuy$44
Latest News
Aug-05-26
Aug-05-2604:01PM
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)globenewswire.com
02:19AM
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcriptseekingalpha.com
Aug-04-26
Aug-04-2611:04PM
Syndax Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
06:16PM
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimateszacks.com
04:03PM
Syndax Pharmaceuticals Q2 EPS $(0.55) Misses $(0.49) Estimate, Sales $72.788M Miss $79.323M EstimateBenzinga
04:01PM
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Updateglobenewswire.com
Jul-28-26
Jul-28-2607:00AM
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026globenewswire.com
Jul-17-26
Jul-17-2601:01PM
Syndax Pharmaceuticals (SNDX) Is Up 8.20% in One Week: What You Should Knowzacks.com
Jul-15-26
Jul-15-2606:29AM
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price TargetBenzinga
04:11AM
Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies Transcriptseekingalpha.com
Jul-14-26
Jul-14-2604:03PM
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Pushmarketbeat.com
10:56AM
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Betzacks.com
08:00AM
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Eventglobenewswire.com
Jul-08-26
Jul-08-2602:00PM
Biotech Euphoria Driven By FundamentalsSeekingAlpha
Jul-01-26
Jul-01-2604:01PM
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)globenewswire.com
Company

Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue25217224——————
Cost of Goods Sold Incl. D&A671——————
Gross Profit24616523——————
Selling, General and Administrative Excl. Other175180121——————
Research and Development262259242——————
Other Operating Expense3-10——————
Operating Income-194-273-340——————
Interest Expense86345——————
Unusual Expense
—————————
Non-Operating Income (Expense)582126——————
Net Income Before Taxes-221-285-319——————
Income Taxes
000——————
Consolidated Net Income-221-285-319——————
Net Income From Continuing Operations-221-285-319——————
Net Income-221-285-319——————
EPS (Recurring)-2.52-3.29-3.73——————
EPS (Basic, Before Extraordinaries)-2.52-3.29-3.73——————
EPS (Diluted)-2.52-3.29-3.73——————
EBITDA-135-252-314——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio7.1910.6347.37——————
Gross Margin97.6295.9395.83——————
Operating Margin-76.98-158.72-1,416.67——————
Net Margin-87.70-165.70-1,329.17——————
Shares Outstanding898786——————
Market Capitalization1,8131,8281,137——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$27.61$22.28$16.94$11.60$6.27● Close Price0.00M0.65M1.29M1.94M2.58MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Metzger Michael AChief Executive OfficerJul 08 '26Sale24.2432,375784,776484,843Jul 09
Metzger Michael AChief Executive OfficerJul 08 '26Option Exercise6.3864,750413,106517,218Jul 09
Botwood Nicholas A.J.Head of R&D, CMOJun 12 '26Option Exercise13.8262,470863,33692,120Jun 12
Botwood Nicholas A.J.Head of R&D, CMOJun 12 '26Sale18.1431,235566,60360,885Jun 12
Botwood Nicholas A.J.Head of R&D, CMOJun 11 '26Sale18.0034,280617,04060,885Jun 12
Botwood Nicholas A.J.Head of R&D, CMOJun 11 '26Option Exercise13.8222,515311,15795,165Jun 12
Goldan Keith A.Chief Financial OfficerJun 01 '26Sale18.991,17722,351139,252Jun 02
Metzger Michael AChief Executive OfficerJun 01 '26Sale18.996,847130,025484,843Jun 02
Metzger Michael AChief Executive OfficerFeb 09 '26Sale21.0317,159360,819491,690Feb 10
Goldan Keith A.Chief Financial OfficerFeb 09 '26Sale21.033,41071,705140,429Feb 10
Goldan Keith A.Chief Financial OfficerFeb 06 '26Sale20.622,08242,931143,839Feb 06
Metzger Michael AChief Executive OfficerFeb 06 '26Sale20.627,412152,835508,849Feb 06
Metzger Michael AChief Executive OfficerSep 08 '25Sale16.41157,3072,582,021298,661Sep 08
Metzger Michael AChief Executive OfficerSep 08 '25Option Exercise10.90314,6143,429,292455,968Sep 08
Podlesak DennisDirectorAug 18 '25Option Exercise7.2019,200138,240210,963Aug 18
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.